Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

70.42
-0.2350-0.33%
Volume:57.57K
Turnover:4.06M
Market Cap:2.40B
PE:-10.89
High:71.41
Open:71.41
Low:70.02
Close:70.65
52wk High:109.00
52wk Low:33.40
Shares:34.14M
Float Shares:28.53M
Volume Ratio:0.41
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:2.66
PE(LYR):-7.24

Loading ...

Nektar Therapeutics Price Target Maintained with a $178.00/Share by BTIG

Dow Jones
·
Sep 09

Nektar Therapeutics - Enters Quiet Period Beginning Sept 8, 2026 Until Phase 2B Rezolve-Aa Study Data - SEC Filing

THOMSON REUTERS
·
Sep 09

Peer‑Reviewed REZOLVE‑AD Phase 2b Data Could Be A Game Changer For Nektar Therapeutics (NKTR)

Simply Wall St.
·
Aug 31

Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Aug 29

Nektar Grants Inducement Equity Awards to New Hires, Including Options Priced at USD 74.53

Reuters
·
Aug 29

Nektar Therapeutics - Rezolve-Ad Study Meets All Primary and Key Secondary Endpoints for Rezpegaldesleukin 24 ΜG/Kg Q2w

THOMSON REUTERS
·
Aug 25

Nektar Therapeutics : JP Morgan Resumes Coverage with Neutral Rating; Target Price $65

THOMSON REUTERS
·
Aug 21

Nektar Therapeutics’ Earnings Call Highlights Rezpeg Momentum

TIPRANKS
·
Aug 21

Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)

TIPRANKS
·
Aug 20

Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?

Simply Wall St.
·
Aug 14

Nektar Therapeutics Falls on Quarterly Revenue Miss

Reuters
·
Aug 14

Nektar Therapeutics Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Earnings Flash (NKTR) Nektar Therapeutics Posts Q2 Loss $1.23 Per Share, vs. FactSet Est of $1.97 Loss

MT Newswires Live
·
Aug 14

Nektar Q2 FY26 Net Loss Narrows to $40.62 Million; Revenue Falls 9.35% to $10.1 Million

Reuters
·
Aug 14

Nektar Q2 2026 Earnings: Phase 3 Spending Rises as Cash and Investments Top $1 Billion

TradingKey
·
Aug 14

Nektar Therapeutics Q2 EPS $(1.23) Beats $(2.00) Estimate, Sales $10.131M Miss $10.425M Estimate

Benzinga Earnings
·
Aug 14

Nektar Therapeutics Q2 EPS USD -1.23

THOMSON REUTERS
·
Aug 14

Earning Preview: Nektar Therapeutics revenue expected to decrease by 3.91%, and institutional views are bullish

Earnings Agent
·
Aug 06

Nektar Therapeutics to Report Q2 Results After U.S. Market Close, Hosts Conference Call

Reuters
·
Jul 29

Is Nektar Therapeutics (NKTR) Undervalued On Its Phase 3 Rezpegaldesleukin Launch?

Simply Wall St.
·
Jul 28